Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes

Diabetologia

Volumn 49, Issue 6, 2006, Pages 1163-1168

  Luzio, S ^a   Dunseath, G ^a   Peter, R ^a   Pauvaday, V ^a   Owens, D R ^a  

^a LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Biphasic insulin aspart; Insulin glargine; Isoglycaemic clamp; Pharmacodynamics; Pharmacokinetics; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; REPAGLINIDE;

ABDOMINAL WALL; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HUMAN; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE;

AGED; AREA UNDER CURVE; BLOOD GLUCOSE; C-PEPTIDE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN; KINETICS; MALE; MIDDLE AGED;

EID: 33646508084     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-006-0243-2     Document Type: Article

References (14)

1. Turner R, Cull C, Frighi V, Holman R (1999) Glycaemic control with diet, sulphonylureas, metformin, or insulin in patients with type 2 diabetes: progressive requirement for multiple therapies (UKPDS). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005-2012
2. UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in people with type 2 diabetes mellitus. Lancet 352:837-853
3. Nathan DM (2002) Initial management of glycaemia in type 2 diabetes mellitus. N Engl J Med 347:1342-1349
4. Owens DR, Zinman B, Boli GB (2001) Insulins today and beyond. Lancet 358:739-746
5. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators (2003) The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080-3086
6. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P et al, INITIATE Study Group (2005) Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28:260-265
7. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H (2005) Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28:254-259
8. Owens DR (1986) Human insulin: clinical pharmacological studies in normal man. MTP Press, Lancaster, UK
9. Hermansen K, Colombo M, Storgaard H et al (2002) Improved postprandial glycaemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 25:883-888
10. Lepore M, Pampanelli S, Fanelli C et al (2000) Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142-2148
11. Kurtzhals P, Schäffer L, Sørensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999-1005
12. Buchanan TA (2003) Pancreatic beta-cell loss and preservation in type 2 diabetes. Clin Ther 25(Suppl B):B32-B46
13. Gerich JE (2003) Clinical significance, pathogenesis, and management of postprandial hyperglycaemia. Arch Intern Med 163:1306-1316
14. The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association Diagnostic criteria, the DECODE Study Group, European Diabetes Epidemiology Group: diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 354: 617-621